注册
忘记密码
忘记用户名
专家账号密码找回
目的 评价三维适形放射治疗（3DCRT）对晚期原发性肝癌（PLC）合并门静脉癌栓（PVTT）患者的疗效，分析肝癌放疗的预后因素。方法 对108例PLC合并PVTT的患者行3DCRT，肿瘤剂量28～63 Gy（中位50.6 Gy），分割剂量2～8 Gy（中位4.0 Gy），每周3～5次，每日或隔日1次。结果 3DCRT总有效率（CR+PR）为40.7%（44/108），1、2、3年生存率分别为37.1%、14.5%、7.8%，中位生存时间8.0个月。多因素分析显示，肝动脉化疗栓塞（TACE）、放疗近期疗效是独立的预后因素。结论 3DCRT对PLC合并PVTT是一种有效的治疗手段， TACE及放疗近期疗效是影响PLC合并PVTT患者放疗的独立预后因素。
当前位置：首页 / 原发性肝癌合并门静脉癌栓放射治疗的预后分析
论著
|
更新时间：2015-07-22
|
原发性肝癌合并门静脉癌栓放射治疗的预后分析
Prognostic analysis of radiotherapy for primary liver cancer complicated with portal vein tumor thrombus
微创医学 201502期 页码：131-135
作者机构：（广西医科大学附属肿瘤医院、广西医科大学研究生学院，南宁市530021）
基金信息：（收稿日期：2015-02-03 修回日期：2015-03-26）作者简介：陆辉荣（1985～），男，硕士，职称，研究方向：肝癌的放射治疗。
- 中文简介
- 英文简介
- 参考文献
)【Abstract】 Objective To evaluate the efficacy of three dimensional conformal radiotherapy (3DCRT) for advanced primary liver cancer (PLC) complicated with portal vein tumor thrombus (PVTT) and analyze the prognostic factors associated with radiotherapy. Methods 108 patients treated with 3DCRT for PLC complicating PVTT between January 2000 and December 2013 were analyzed. The radiotherapy schedule was 28-63 Gy (median 50.6 Gy) in 2-8 Gy (median 4.0 Gy)/fraction, 3-5 fractions/week, once a day or every other day. Results The total effective rate (CR + PR) was 40.7% (44/108), with a 1-, 2-, 3- year survival rate of 37.1%, 14.5% and 7.8%, respectively. The median survival time was 8.0 months. In a multivariate analysis, artery chemoembolization(TACE) and shortterm response to radiotherapy were found to be statistically significant. Conclusion 3DCRT is an effective treatment for PLC complicating PVTT, TACE and shortterm response to radiotherapy may be independent prognostic factors for PLC complicating PVTT
- ref
下载
收藏
